The global opioid induced constipation treatment market is witnessing steady growth as opioid use continues to expand across chronic pain management, cancer care, and post-surgical treatment. Valued at US$ 2.9 billion in 2025, the market is projected to reach US$ 5.2 billion by 2036, advancing at a CAGR of 5.3% from 2026 to 2036. Rising awareness of opioid-induced constipation (OIC), an aging population, and increasing demand for supportive therapies are expected to sustain market expansion.

Market Highlights

  • Market value reached US$ 2.9 billion in 2025.
  • Revenue is expected to reach US$ 5.2 billion by 2036.
  • The market is projected to grow at a 5.3% CAGR between 2026 and 2036.
  • North America dominated the market with a 43.7% revenue share in 2025.
  • PAMORAs accounted for the leading therapy segment, with a 65.4% share in 2025.
  • Major companies include AstraZeneca, DAIICHI SANKYO COMPANY, LIMITED, and Takeda Pharmaceutical Company Limited.

Rising Chronic Pain Cases Drive Market Growth

The growing prevalence of chronic pain conditions, including arthritis, cancer-related pain, and neuropathic disorders, is a major factor supporting demand for OIC treatments. Patients receiving long-term opioid therapy are particularly vulnerable to gastrointestinal side effects because opioids can reduce intestinal motility and alter fluid secretion.

As healthcare providers increasingly focus on comprehensive pain management, treating opioid-related adverse effects has become an important component of patient care. This is creating demand for therapies that can relieve constipation without compromising the analgesic benefits of opioid medicines.

Growing patient education and awareness are also encouraging earlier recognition and treatment of OIC. Pharmaceutical companies are consequently investing in targeted therapies, clinical research, and patient-support programs to address this unmet need.

Increasing Opioid Use Supports Demand for OIC Therapies

Opioids remain important medicines for managing moderate to severe pain associated with cancer, surgery, chronic illnesses, and other conditions. However, constipation is one of their common gastrointestinal side effects. As opioid use increases, the need for effective and tolerable constipation treatments is expected to grow alongside it.

Traditional approaches such as laxatives, stool softeners, dietary changes, and increased fluid intake may provide relief but do not directly address opioid activity at gastrointestinal receptors. This limitation has increased interest in targeted pharmacological therapies.

Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862

PAMORAs Lead the Therapy Segment

Peripherally Acting µ-Opioid Receptor Antagonists (PAMORAs) represent the leading therapy segment in the global OIC treatment market. These therapies are designed to counteract opioid activity in the gastrointestinal tract while preserving the central analgesic effects of opioids.

Their targeted mechanism has made PAMORAs an important advancement in OIC management. Continued product innovation, clinical evidence, and increasing physician awareness are likely to support their adoption during the forecast period.

North America Maintains Market Leadership

North America accounted for the largest regional share of the opioid induced constipation treatment market in 2025, at 43.7%. The region benefits from high opioid utilization for chronic and post-surgical pain, established healthcare infrastructure, greater awareness of OIC, and strong pharmaceutical research capabilities.

Favorable reimbursement environments, product innovation, and the presence of major pharmaceutical companies are also supporting regional growth. As healthcare systems increasingly emphasize quality of life and treatment adherence, demand for targeted OIC therapies is expected to remain strong.

Competitive Landscape

The competitive environment is characterized by research and development investments, strategic partnerships, product portfolio expansion, regulatory submissions, and patient-support initiatives. Leading participants include Salix Pharmaceuticals, AstraZeneca, DAIICHI SANKYO COMPANY, LIMITED, Takeda Pharmaceutical Company Limited, Mallinckrodt, Shionogi & Co., Ltd., Ironwood, Nektar Therapeutics, and Cigna Healthcare.

Overall, increasing opioid exposure, growing chronic pain prevalence, and rising recognition of OIC are expected to create sustained opportunities in the market through 2036.

Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453